论文部分内容阅读
1 临床资料 1.1 一般资料 49例患者均为我院1998年住院病人,诊断符合1995年5月北京第5次全国传染病寄生虫病学术会议讨论修订的病毒性肝炎防治方案(试行)诊断标准,随机分为两组:治疗组26例,男23例,女3例,平均年龄:33.4±8.3岁,平均发病天数13.2±4.9,其中乙型肝炎22例,甲型肝炎1例,甲乙型肝炎病毒重叠感染2例。对照组23例,男性22例,女性1例,平均年龄30.7±10.8岁,平均发病天数10.8±5.6,其中乙肝22例,甲乙型肝炎病毒重叠感染1例。两组患者在性别、年龄、病程、病情等方面比较均无统计学差异(P>0.05)。 1.2 治疗方法 治疗组:促肝细胞生长素80～100mg,加入
1 Clinical data 1.1 General information 49 patients were hospitalized in 1998 in our hospital, the diagnosis was in line with the Fifth National Conference on Infectious Diseases Parasitic Diseases in Beijing in May 1995 to discuss the revision of the diagnostic criteria for the prevention and treatment of viral hepatitis (trial) The patients in the treatment group were divided into two groups at random: 26 cases in the treatment group, 23 males and 3 females, with an average age of 33.4 ± 8.3 years and an average onset of 13.2 ± 4.9 days, of which 22 were hepatitis B, 1 was hepatitis A and 1 was hepatitis B Two cases of virus infection. The control group of 23 cases, 22 males and 1 female, with an average age of 30.7 ± 10.8 years, the average number of days of onset was 10.8 ± 5.6, of which 22 cases of hepatitis B, hepatitis A and hepatitis B virus infection in 1 case. There was no significant difference between the two groups in terms of sex, age, course of disease, disease and other aspects (P> 0.05). 1.2 treatment group: promote hepatocyte growth hormone 80 ~ 100mg, added